Aggregated China Business Blogs



Aoxing Pharmaceutical's Anti-Opioid Addiction Drug Approved by China’s FDA

Aggregated Source: China Stocks News and Analysis from Seeking Alpha
December 4, 2007|

Dai Jialing submits: China’s State Food and Drug Administration approved a research and development license Nov. 20 for Aoxing Pharmaceutical's (CAXG.OB) opioid combo tablet buprenorphine/naloxone tailored to fight the growing problem of opioid dependence in China.

Original URL: Click here to visit original article
Copyright China Stocks News and Analysis from Seeking Alpha

Print This Post Print This Post | Email This Page Email This Page
No Ratings Yet
Loading ... Loading ...

Related Info:
  • China Aoxing Granted License for Addiction Drug, Still Lacks Firm Financial Footing
  • China Aoxing Receives Manufacturing Exclusivity for Cancer Pain Drug
  • AIDA Pharmaceuticals Announces Favorable Clinical Trial Findings
  • China Aoxing Pharmaceutical To Acquire Shijiazhuang Company
  • Tongjitang's Osteoperosis Drug Likely to Win FDA Approval

    • No Comments Yet »

    Your comment

    The following HTML tags are permitted:
    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

    RSS RSS Feed for Comments on this Post |